Madrigal Pharmaceuticals, Inc. (MDGL)

194.38 -10.27 (-5.02%) 收市：04:00PM EDT

Madrigal Pharmaceuticals, Inc.

Four Tower Bridge
Suite 200 200 Barr Harbor Drive
West Conshohocken, PA 19428
United States
267 824 2827
https://www.madrigalpharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 376

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Rebecca A. Taub M.D.	Founder, Chief Medical Officer, President of Research & Development and Director	939.83k	無	1952
Mr. Brian J. Lynch J.D.	Senior VP & General Counsel	763.75k	1.27M	1962
Mr. Alex G. Howarth	Executive Officer	757.26k	無	1969
Mr. William J. Sibold	CEO, President & Director	無	無	1966
Ms. Mardi C. Dier	CFO, Principal Financial Officer, Principal Accounting Officer & Senior VP	無	無	1964
Mr. Ronald Filippo	Chief Information Officer	無	無	無
Ms. Tina E. Ventura	Chief Investor Relations Officer	無	無	無
Dr. Kianoush Motesharei Ph.d.	Senior Vice President of Business & Corporate Development	無	無	1970
Mr. Clint Wallace	Chief Human Resources Officer	無	無	無
Mr. Edward Chiang	Senior Vice President of Clinical & Technical Operations	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

公司管治

截至 2024年4月1日 止，Madrigal Pharmaceuticals, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：3；董事會：9；股東權利：8；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。